title: [Hepatocellular Carcinoma: therapeutic options 2015].
abstract: The incidence of hepatocellular carcinoma (HCC), a common neoplasm, is rising and the prognosis is poor. Many factors have to be taken into account when deciding on the best mode of therapy, like tumor size and number, liver function, sequelae of portal hypertension or other comorbidities. These factors are reflected in the Barcelona Clinic Liver Cancer (BCLC) classification. Resection, radiofrequency ablation (RFA) and liver transplantation can be seen as curative therapies for the early and localized HCC. For the intermediate state of the HCC, there are other therapeutic modalities in therapy available: transarterial chemoembolization (TACE), selective internal radiation therapy (SIRT, rarer occasions), off label: stereotactic body radiation therapy (SBRT). At the moment, Sorafenib is the only option in treating advanced stages of HCC. Alternative treatment strategies, like e.g. immunological therapies, are being investigated.
authors.affiliation: Klinik für Innere Medizin, Universitätsklinikum Freiburg.
authors.forename: Michael
authors.initials: M
authors.lastname: Schultheiß
authors.affiliation: Klinik für Innere Medizin, Universitätsklinikum Freiburg.
authors.forename: Dominik
authors.initials: D
authors.lastname: Bettinger
authors.affiliation: Klinik für Innere Medizin, Universitätsklinikum Freiburg.
authors.forename: Hannes P
authors.initials: HP
authors.lastname: Neeff
authors.affiliation: Klinik für Innere Medizin, Universitätsklinikum Freiburg.
authors.forename: Thomas B
authors.initials: TB
authors.lastname: Brunner
authors.affiliation: Klinik für Innere Medizin, Universitätsklinikum Freiburg.
authors.forename: Robert
authors.initials: R
authors.lastname: Thimme
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D059248:Chemoradiotherapy / Q000379:methods*; D003131:Combined Modality Therapy / Q000379:methods; D019317:Evidence-Based Medicine; D006801:Humans; D038622:Internationality; D008113:Liver Neoplasms / Q000175:diagnosis / Q000628:therapy*; D016031:Liver Transplantation; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000008:administration & dosage*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib